亚临床房颤中根据CHA2DS2-VASc评分选择阿哌沙班或阿司匹林:ARTESiA研究启示
ARTESiA研究的事后亚组分析按基线CHA2DS2-VASc评分评估阿哌沙班与阿司匹林在亚临床房颤患者中的疗效与安全性。结果显示,评分>4的患者使用阿哌沙班预防卒中/系统性栓塞的获益大于出血风险,而评分<4者相反,评分=4者需结合患者偏好决策。
要点
- CHA2DS2-VASc>4的亚临床房颤患者,阿哌沙班较阿司匹林显著减少卒中/系统性栓塞,净获益大于出血风险。
- CHA2DS2-VASc<4的患者,阿哌沙班预防卒中/系统性栓塞的获益不明显,而出血风险增加,净获益不利。
- CHA2DS2-VASc=4的患者处于中间状态,治疗决策应结合患者偏好个体化。
核心结论
- 在亚临床房颤患者中,CHA2DS2-VASc评分>4者使用阿哌沙班预防卒中/系统性栓塞的获益大于风险,评分<4者则相反,评分=4者需个体化决策。
研究设计与样本
- ARTESiA研究的事后亚组分析,按基线CHA2DS2-VASc评分分组,评估阿哌沙班与阿司匹林在卒中/系统性栓塞及大出血方面的相对和绝对差异。
- 基线CHA2DS2-VASc评分<4者1578例(39.4%),=4者1349例(33.6%),>4者1085例(27.0%)。
主要发现
- CHA2DS2-VASc>4患者中,阿哌沙班组卒中率为0.98%/年,阿司匹林组为2.25%/年。
- CHA2DS2-VASc>4患者中,阿哌沙班较阿司匹林每100患者年预防1.28(95%CI:0.43-2.12)例卒中/系统性栓塞,导致0.68(95%CI:-0.23至1.57)例大出血。
- CHA2DS2-VASc<4患者中,阿哌沙班组卒中/系统性栓塞率为0.85%/年,阿司匹林组为0.97%/年。
- CHA2DS2-VASc<4患者中,阿哌沙班每100患者年预防0.12(95%CI:-0.38至0.62)例卒中/系统性栓塞,导致0.33(95%CI:-0.27至0.92)例大出血。
- CHA2DS2-VASc=4患者中,阿哌沙班每100患者年预防0.32(95%CI:-0.16至0.79)例卒中/系统性栓塞,导致0.28(95%CI:-0.30至0.86)例大出血。
临床怎么用
- 对亚临床房颤患者,应计算基线CHA2DS2-VASc评分以指导抗栓决策。
- CHA2DS2-VASc>4者可优先考虑阿哌沙班以降低卒中/系统性栓塞风险。
- CHA2DS2-VASc<4者使用阿哌沙班净获益不利,应谨慎评估。
- CHA2DS2-VASc=4者需结合患者偏好进行个体化治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: ARTESiA (Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation) demonstrated that apixaban, compared with aspirin, significantly reduced stroke and systemic embolism (SE) but increased major bleeding in patients with subclinical atrial fibrillation. OBJECTIVES: To help inform decision making, the authors evaluated the efficacy and safety of apixaban according to baseline CHA2DS2-VASc score. METHODS: We performed a subgroup analysis according to baseline CHA2DS2-VASc score and assessed both the relative and absolute differences in stroke/SE and major bleeding. RESULTS: Baseline CHA2DS2-VASc scores were <4 in 1,578 (39.4%) patients, 4 in 1,349 (33.6%), and >4 in 1,085 (27.0%). For patients with CHA2DS2-VASc >4, the rate of stroke was 0.98%/year with apixaban and 2.25%/year with aspirin; compared with aspirin, apixaban prevented 1.28 (95% CI: 0.43-2.12) strokes/SE per 100 patient-years and caused 0.68 (95% CI: -0.23 to 1.57) major bleeds. For CHA2DS2-VASc <4, the stroke/SE rate was 0.85%/year with apixaban and 0.97%/year with aspirin. Apixaban prevented 0.12 (95% CI: -0.38 to 0.62) strokes/SE per 100 patient-years and caused 0.33 (95% CI: -0.27 to 0.92) major bleeds. For patients with CHA2DS2-VASc =4, apixaban prevented 0.32 (95% CI: -0.16 to 0.79) strokes/SE per 100 patient-years and caused 0.28 (95% CI: -0.30 to 0.86) major bleeds. CONCLUSIONS: One in 4 patients in ARTESiA with subclinical atrial fibrillation had a CHA2DS2-VASc score >4 and a stroke/SE risk of 2.2% per year. For these patients, the benefits of treatment with apixaban in preventing stroke/SE are greater than the risks. The opposite is true for patients with CHA2DS2-VASc score <4. A substantial intermediate group (CHA2DS2-VASc =4) exists in which patient preferences will inform treatment decisions. (Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation; NCT01938248).
引用
- Lopes, Granger, Wojdyla, et al. Apixaban vs Aspirin According to CHA2DS2-VASc Score in Subclinical Atrial Fibrillation: Insights From ARTESiA. J Am Coll Cardiol. 2024. PMID: 39019530. doi:10.1016/j.jacc.2024.05.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。